Redesigned test introduces two new targets to improve coverage and sensitivity for Group B Streptococcus intrapartum testing for pregnant females Group B Streptococcus (GBS) is the leading cause of ...

SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received FDA Clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert® Xpress MVP. This ...

Cepheid announced that it has received US FDA clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert Xpress MVP. This multiplex vaginal panel can now be performed in ...

Cepheid announced it has received the CE mark for Xpert Xpress CoV-2 plus, a rapid molecular diagnostic test for qualitative detection of the virus that causes Covid-19. Viruses constantly change ...

Multiplex Vaginal Panel (MVP) delivers faster identification of three distinct conditions within an hour SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received ...

SUNNYVALE, Calif., March 11, 2024 /PRNewswire/ -- Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular ...

Redesigned test introduces two new targets to improve coverage and sensitivity for Group B Streptococcus intrapartum testing for pregnant females With the capability of returning positive results as ...

SUNNYVALE, Calif., Jan. 9, 2018 /PRNewswire/ -- Cepheid announced today it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) ...

Multiplex Vaginal Panel (MVP) delivers faster identification of three distinct conditions within an hour "Misdiagnosis of the specific underlying causes of vaginitis and vaginosis often lead to ...

SUNNYVALE, Calif., May 2, 2018 /PRNewswire/ -- Cepheid announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and waiver under the Clinical Laboratory ...